NDAINTRATHECALINJECTABLEPriority Review
Approved
Dec 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRIALT (ziconotide acetate) is a small-molecule intrathecal injectable approved in 2004 for severe chronic pain management. It is a selective neuronal N-type calcium channel blocker that works by reducing neurotransmitter release in the spinal cord. The drug is indicated for patients with severe chronic pain who are intolerant to or refractory to other treatment modalities.
$0.099MPart D
LOE ApproachingLimited commercial expansion opportunity as the product faces patent expiration; small sales team focused on specialty pain management centers suggests niche, stable positioning rather than growth trajectory.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
OP2C : Prialt® Observatory in Clinical Practice
Started Jul 2020
300 enrolled
Refractory Pain
Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.
Started Apr 2008
219 enrolled
Pain ManagementSevere Chronic Pain
Career Relevance
Careers on PRIALT are concentrated in specialty-focused commercial roles serving a small, well-defined patient population in pain management centers and specialty hospitals. This is a niche, stable position suited for professionals seeking deep expertise in rare/severe disease management rather than broad-market commercial growth.
Worked on PRIALT at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.